Patheon
A HEALTHIER WORLD. DELIVERED.



Patheon Presentation

Biotuesday

March 2016



Patheon®

A HEALTHIER WORLD. DELIVERED.

Patheon is a leading provider of contract development and commercial manufacturing services to the pharmaceutical & biotechnology sectors.

We offer the broadest set of solutions to clients including development and commercial manufacturing services for both large and small molecule drug substance and drug product in a wide range of dosage forms.

Inspire & Simplify.

Patheon
Performance the World Over®

Legacy Patheon business had a strong **PDS and DPS offering**

2011

Appointed **James C. Mullen** as Chief Executive Officer and to Board of Directors

2012

BANNER LIFE SCIENCES

Acquisition of **Banner Pharmacaps**, a market leader in **soft gelatin capsule technology**, adding a new proprietary products and technology business



2013

DPx

DPx was formed as a part of a $2.7 billion transaction between JLL Partners and Royal DSM

2014

gallus

Acquisition of **Gallus BioPharmaceuticals,** adding North American capabilities to its existing biologics operations in Groningen, Netherlands and Brisbane, Australia

2015

IRIX

Acquisition of **IRIX** added North American API services

agere PHARMACEUTICALS

Acquisition of **Agere** added low solubility

Pharm Source

PharmSource Report cites Patheon winning the greatest % of NMEs and non-NMEs over the last 10 years

Patheon
A HEALTHIER WORLD. DELIVERED.

Single Source Provider, End-to-End



Single Source Provider, End-to-End



Patheon
A HEALTHIER WORLD. DELIVERED.

Single Source Provider, End-to-End



A Recognized Leader in Contract Development and Manufacturing

Contract Pharmaceutical Development Market[1]

Patheon #1



The contract development market was worth $1.9B in 2013

Patheon is the market leader with a 9% share

Contract Pharmaceutical Manufacturing Market[2]

Patheon #2



The highly fragmented manufacturing market was worth $15.1B in 2013

Patheon is second in the market with a 7% share

[1]Source: PharmSource estimates, 2014. Development market estimate includes preformulation, formulation, and clinical dose manufacturing.
[2]Source: PharmSource estimates, 2014. Contract Manufacturing market estimate excludes enhanced packaging. Includes DPP data

Patheon
A HEALTHIER WORLD. DELIVERED.

Patheon is a Global Service Provider

More than 25 locations across
North America, Europe, Latin America & Australia



As of April 2015

Patheon
A HEALTHIER WORLD. DELIVERED.

Patheon Bourgoin Overview

- ✓ Pharmaceutical site since 1960’
- ✓ PATHEON site since1999

- ✓ Manufacturing Area: 25 250 m^2
- ✓ Employees: 262 (Commercial) + 50 (Development Services)

Patheon
A HEALTHIER WORLD. DELIVERED.

Bourgoin Overview

Site authorized and focused on High-potent compounds (up to Cat3B)

PDS (Development) co-located with **commercial plant (DPS)**.

Solid oral dosage forms manufacturing

Compatible processes to allow smooth scale up of solid dose manufacturing processes from

- ✓ clinical batches and small commercial batches (5 – 150 kg) to
- ✓ larger commercial (150 – 750kg) process scales

EU Center of Excellence Packaging: blisters, bottling, sachets

Patheon
A HEALTHIER WORLD. DELIVERED.

Regulatory and inspection history

- The Bourgoin facility is routinely inspected by both its international clients and its local Regulatory Body – ANSM.
- **ANSM approved site (June 2014)**
- **US FDA approved site (March 2014)**
- **PMDA** accreditation (Japanese authority) **(February 2012)**
- The facility is approved for all European countries, Canada, New Zealand, Australia, Kenya and Japan through mutual recognition (MRAs)
- Shipment to worldwilde destinations such as, Asia, MEAF, South America etc.

Date of Inspection	Regulatory Authority	Inspection Type
Nov 2015	ANSM	GMP
June 2015	ANVISA	GMP
March 2015	Kenyan Inspection	GMP
November 2014	Turkish Inspection	GMP
June 2014	ANSM (France)	GMP
March 2014	FDA	PAI
December 2013	Turkish Inspection	GMP
April 2012	ANSM (France)	GMP
July 2011	ANSM (France) for PDS	GMP
November 2009	ANSM (France)	GMP
November 2008	KFDA (Korea)	PAI
July 2008	GISK (Russia)	GMP
June 2008	ANVISA	GMP



PRODUCT DEVELOPMENT SERVICES PDS

October 2015

Product Development Services Growth

Built in 2010 – Started in 2011



Patheon
A HEALTHIER WORLD. DELIVERED.

High Potent Oral Solid Dose Center Of Excellence

Seamless contained development and manufacturing service

- Safely APIs process with a minimum OEB 4 / OELs >10 ng/m^3 (Cat 3b)

-Contained processing design concept to minimise the need for PPE (personal protective equipment) for routine operations. Compliant with Big Pharma HiPo Health-Security-Environment internal rules

- Design-for-manufacture approach enabling reproducibility from development scale (1kg) to commercial scale



Bourgoin Development Services Capabilities

Technologies

- High potency containment at source
- Powder blending (5 - 150 kg)
- Granulation (30 - 150 kg)
- Dry compaction
- Compression (conventional, minitabs & bilayer tablets)
- Coating
- Encapsulation

Packaging

- Semi automatic packaging lines:
  - Bottles
  - Blisters (PVC, PVDC, Aclar®)

Dosage forms

- Tablets
- Capsules
- Sachets
- Oral Solutions

Services

- Clinical supply
- Process Development
- Quality by Design
- DoE
- Small scale commercial supply

Exemples de produits hautement actifs novateurs développés sur le site de Bourgoin-Jallieu

Projet P232: traitement du cancer du myélome, Leucémie aigue (US)

Projet P470: traitement du cancer de la prostate (US)

Projet P448: traitement du cancer de la prostate (Finland)

Projet P549: traitement des tumeurs solides, cancer du sein / des poumons, (France)

Projet P497: traitement de la leucémie aigue (Japan)

Projet P513: traitement de la maladie de Parkinson (Switzerland)

Projet P460: traitement du cancer du sein (US)



Contact

Francois Berthier: Pharmaceutical Expert & Innovation Contact

Patheon

40 Boulevard de Champaret - CS 11006

38307 Bourgoin-Jallieu Cedex France

Phone: +33 (0)4 74 93 87 63

Mobile: +33 (0)6 46 63 52 62

Fax: +33 (0)4 74 93 87 94

francois.berthier@patheon.com